Vomiting, diarrhea and aversion for meat?

Lysinuric protein intolerance: a case report

Tobler C.1, Bajwa N.1, Kern I.2

General Pediatrics Division1, Pediatric Nephrology and Metabolism Division2

Geneva University Hospitals

Introduction

- Lysinuric protein intolerance (LPI) is a rare autosomal recessive metabolic disease that affects the SCL7A7 gene coding for the light subunit of an amino acid (AA) transporter (γ-LAT1 protein), present mainly in the intestinal and renal tubular cells and on macrophages
- Symptoms include recurrent vomiting and diarrhea, episodes of coma after protein-rich meal, aversion for protein-rich food, failure to thrive, muscular hypotonia
- Complications include hyperammonemia with coma, severe lung disease with pulmonary alveolar proteinosis, renal disease, macrophagic activation syndrome (MAS), immune deficiency and osteopenia

Physiopathology

- Quick reminder: ingestion of proteins → catabolism of proteins into AA (carrying a toxic NH3 ammonia molecule) → transformation of NH3 into urea (less toxic) → renal elimination
- In LPI: ↓ renal and intestinal reabsorption of lysine, arginine and ornithine → ↓ plasmatic concentration of these AA → ↓ substrates for the urea cycle → ↓ urea production = ↓ ammonium excretion → ↑ plasmatic concentration of ammonium

Case report

- 6-year-old girl, arriving from Macedonia
- Clinical picture:
  - Recurrent episodes of vomiting and diarrhea since introduction of formula (2 months old)
  - Episodes of altered consciousness after protein-rich meal
  - Aversion for meat
  - Fatigue (especially during sport)
  - Multiple infections
  - Important failure to thrive
- Clinical features:
  - Height <P3, weight <P3, head circumference <P3
  - Flattened face, short philtrum, low set ears
  - Hepatomegaly
- Laboratory findings:
  - Plasma: anemia (104 g/L), low lysine (35 umol/L) and other AA, hypoproteinemia (pre-albumine 103 mg/L), signs of MAS (ferritine 2’013 ug/L, LDH 980 U/L), normal ammonia (26 umol/L)
  - Urine: High lysine (344 umol/mol) and arginine (19 mmol/mol), normal ornithine (6 umol/mol)
- Treatments:
  - Prevent hyperammonemia by improving the urea cycle: low protein diet (0.8-1.5g/kg/d), citrulline +/- sodium benzoate

Conclusion

- LPI is a rare metabolic disease
- Range of symptoms from nausea to coma and death
- Treatment quickly improves symptoms
- Follow-up necessary to prevent pulmonary and renal complications

References

* "Lysinuric Protein Intolerance: Reviewing Concepts on a Multisystem Disease", GIANFRANCO SEBASTIO,* MARIA P. SPERANDEO, AND GENEROSO ANDRIA, American Journal of Medical Genetics Part C (Seminars in Medical Genetics) 157:54–62 (2011)
* "Lysinuric protein intolerance.«, Virginia Nunes, PhD and Harri Niinikoski, MD PhD, GeneReview, 2006 Dec 21
* Picture: canva.com